Patents by Inventor Chung Gyu Park

Chung Gyu Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL ANTI-CD4O ANTIBODIES AND USE THEREOF
    Publication number: 20220112298
    Abstract: The present invention relates to novel anti-CD40 antibodies and a use thereof and, more specifically, provided are a pharmaceutical composition for treating or preventing autoimmune diseases and a composition for inhibiting immune rejection during organ transplantation, both compositions containing, as an active ingredient, novel anti-CD40 antibodies that specifically bind to a novel epitope of CD40. Novel anti-CD40 antibodies of the present invention directly target CD40, but not CD40 ligands, and block the signaling of CD40-CD154 without stimulating platelets so as to exhibit excellent antagonistic effects, thereby being expected to be usable as a preparation effective in the treatment of autoimmune diseases and the inhibition of organ transplantation rejection.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Inventors: Chung Gyu Park, Jung Sik Kim
  • Anti-CD40 antibody and methods for blocking CD40-CD40L signaling
    Patent number: 11242397
    Abstract: The present invention relates to novel anti-CD40 antibodies and a use thereof and, more specifically, provided are a pharmaceutical composition for treating or preventing autoimmune diseases and a composition for inhibiting immune rejection during organ transplantation, both compositions containing, as an active ingredient, novel anti-CD40 antibodies that specifically bind to a novel epitope of CD40. Novel anti-CD40 antibodies of the present invention directly target CD40, but not CD40 ligands, and block the signaling of CD40-CD154 without stimulating platelets so as to exhibit excellent antagonistic effects, thereby being expected to be usable as a preparation effective in the treatment of autoimmune diseases and the inhibition of organ transplantation rejection.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: February 8, 2022
    Assignee: PB Immune Therapeutics Inc.
    Inventors: Chung Gyu Park, Jung Sik Kim
  • NOVEL ANTI-CD40 ANTIBODIES AND USE THEREOF
    Publication number: 20200291123
    Abstract: The present invention relates to novel anti-CD40 antibodies and a use thereof and, more specifically, provided are a pharmaceutical composition for treating or preventing autoimmune diseases and a composition for inhibiting immune rejection during organ transplantation, both compositions containing, as an active ingredient, novel anti-CD40 antibodies that specifically bind to a novel epitope of CD40. Novel anti-CD40 antibodies of the present invention directly target CD40, but not CD40 ligands, and block the signaling of CD40-CD154 without stimulating platelets so as to exhibit excellent antagonistic effects, thereby being expected to be usable as a preparation effective in the treatment of autoimmune diseases and the inhibition of organ transplantation rejection.
    Type: Application
    Filed: June 1, 2018
    Publication date: September 17, 2020
    Inventors: Chung Gyu Park, Jung Sik Kim